Approximately one in five patients treated for hypertension in the United States has apparently resistant blood pressure, defined as readings of 130/80 mm Hg or higher despite taking three or more antihypertensive medications, according to a review published online March 23, 2026, in JAMA.
The study, led by researchers including Azizi M, Vongpatanasin W, Fisher NDL, Mahfoud F, Amar L, and Kirtane AJ, found that about 19.7% of treated hypertensive patients meet this criterion when using a regimen that ideally includes a renin-angiotensin system blocker, a calcium channel blocker, and a thiazide diuretic at maximally tolerated doses.
However, true resistant hypertension—confirmed through 24-hour ambulatory or home blood pressure monitoring to rule out white coat effect—is present in only about 10% of treated patients. This figure reflects adjustments for non-adherence (which accounts for roughly 50% of apparent resistance) and secondary causes such as primary aldosteronism (found in 5% to 25% of cases).
The researchers noted that conditions commonly associated with resistant hypertension include obesity, diabetes, chronic kidney disease, and sleep apnea. Patients with uncontrolled resistant hypertension face a significantly higher risk of cardiovascular death over five to ten years compared to those with controlled blood pressure, with an absolute risk increase of 10.3% (95% CI, 8.7%-12.1%).
The findings underscore the importance of accurate diagnosis and tailored treatment strategies, as misidentifying resistant hypertension can lead to unnecessary interventions while overlooking reversible factors like medication non-adherence or secondary endocrine disorders.
